培美曲塞联合顺铂治疗晚期食道癌的疗效观察

Clinical observation of pemetrexed and cisplatin combination in the treatment of metastatic esophageal cancer

目的：观察培美曲塞联合顺铂方案治疗晚期食道癌的近期疗效及不良反应.方法：27例晚期食道癌患者,以培美曲塞联合顺铂化疗方案：培美曲塞500mg/m2＋顺铂75mg/m2,每3周重复.2个化疗周期后评价疗效和不良反应.结果：27例患者均可评价临床疗效及不良反应,CR0例,PR10例,SD6例,PD11例.中位TTP为4.2个月,中位OS为6.1个月.最常见的不良反应是消化道反应和白细胞下降.结论：培美曲塞联合顺铂是治疗晚期癌的有效方案,且不良反应耐受性较好.

Objective To evaluate the clinical efficacy and tolerability of the treatment of pemetrexed combined with cisplatin for patients suffering from metastatic esophageal cancer. Methods Twenty seven patients suffering from metastatic esophageal cancer were received pemetrexed and cisplatin combination regimen,pemetrexed 500 mg/m^2 intravenous infusion, cisplatin 75 mg/m^2 intravenous drip, repeated every3 weeks. Evaluation of clinical efficacy and adverse reactions were carried out after 2 cycles chemotherapy. Cancer progression and pantient＇s overall survival were also evaluated. Results Twertty seven patients completed 2 cycles of chemotherapy. The median time to progression was 4. 2 months, and median overall survival time was 6.1 months. The most common adverse effects were the gastrointestinal reaction and Neutropenia. Conclusions Although patients with metastatic esophageal cancer have variety of chemotherapeutic drug resistance, the combined chemotherapy of pemetrexed and cisplatin is still effective for metastatic esophageal cancer patients. The hematologic and non hematologic toxicities are well tolerated.